Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Invivyd ( (IVVD) ) is now available.
On January 8, 2026, Invivyd reported preliminary fourth-quarter 2025 net product revenue of $17.2 million from its COVID-19 prophylactic antibody PEMGARDA (pemivibart), reflecting 25% year-over-year and 31% sequential growth, and said year-end 2025 cash and cash equivalents stood at $226.7 million following more than $200 million in second-half financing, strengthening its capacity to fund late-stage development and commercialization efforts. The company highlighted the December 2025 initiation of DECLARATION, a Phase 3 pivotal trial of its vaccine-alternative antibody VYD2311 for COVID prevention, which already has U.S. FDA Fast Track designation, and detailed pipeline expansion with the nomination of potential best-in-class RSV antibody VBY329 for pediatric prophylaxis and ongoing discovery work on ultra-long half-life RSV and measles antibodies, underscoring Invivyd’s bid to establish monoclonal antibody prophylaxis as a new standard of care and broaden its footprint in large, fast-growing infectious disease markets.
The most recent analyst rating on (IVVD) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
The score is held back most by weak financial performance—large ongoing losses and significant free-cash-flow burn despite strong gross margins and revenue growth. Offsetting factors include solid technical momentum (price above key moving averages with positive MACD), and a more favorable catalyst setup from the earnings call and recent FDA Fast Track/pipeline events; valuation support is limited because the company is still loss-making.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc., based in New Haven, Connecticut, is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies as vaccine alternatives or complements for preventing and treating infectious diseases, with a current commercial focus on COVID-19 prophylaxis for immunocompromised and other high‑risk populations and an expanding pipeline targeting RSV and measles.
Average Trading Volume: 7,335,876
Technical Sentiment Signal: Buy
Current Market Cap: $659.6M
For detailed information about IVVD stock, go to TipRanks’ Stock Analysis page.